News

Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.

One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place and last.

BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the momentum to last.

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

Moderna and Merck are surging today after the two companies said their experimental mRNA-based treatment succeeded in a late-stage study of high-risk melanoma patients. The SPDR S&P Biotech ETF (XBI) jumped nearly 5%, while the NYSE Arca Pharmaceutical Index climbed over 3%. A positive clinical-trial result typically moves the companies developing the drug—and perhaps their closest competitors—not the entire healthcare sector.

PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.

Headwinds in the sector are clearing. That is good news for venture firms seeking liquidity and for a stock market looking for growth stories, Nilesh Kumar writes in a guest commentary.

Several stocks have recently seen notable insider buys from CEOs, including a $10 million dollar bet from a semiconductor favorite.

A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have finally crossed the line from promising to proven.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

With stocks in bullish mode it’s a good time to run Barchart’s Bull Call Spread Screener.

Ben Zercher is senior analyst of biotech and pharma at PitchBook Obesity drugs offered the holy grail of drug development: a massive market, biology that works, and a proven blueprint paved by blockbuster GLP-1s. But the gold rush led by Big Pharma and investors has ended. The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed. Pfizer just axed another program from its massive Metsera deal, while peers like Amgen have begun trimming their own early-stag

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.8% and the

Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease vaccine candidate validated by the European Medicines Agency, confirming it is ready for full review. The vaccine filing follows late stage clinical results that reported encouraging efficacy and safety in preventing Lyme disease. A recent patent report highlighted Pfizer as a leading holder of next generation antibody drug conjugate intellectual property in cancer treatment. For readers looking...

Bruce Berkowitz has built his entire Fairholme portfolio around a single Northwest Florida land developer, and the boldness of that bet raises a question every retail investor should answer before following his lead.

Nike stock has fallen 38% in 2026 as the sportswear giant’s turnaround drags on, but some analysts still see signs of progress.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.

Even if Berkshire Hathaway never scoops up a stake on this largely overlooked and mostly unloved name, that doesn't mean it doesn't have a place in your portfolio.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec

The biosimilar drag on Johnson & Johnson stock is shrinking, and the business underneath it is already growing at a double-digit pace.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With fresh product news and shifting expectations around its portfolio, investors are weighing whether the recent rebound leaves enough room for attractive long term returns. The share price is down about 28% over five years. This points to a company that has yet to fully reward long term holders...